Trial Number



Bacterial Infection

Participant Age Range

18 years and younger

Participant Gender


Enrolling Participants



A Phase 1, Open-Label, Two-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Intravenous Lefamulin in Hospitalized Pediatric Subjects Receiving Standard of Care Antibiotic Therapy for Confirmed or Suspected Infection

Lefamulin is a novel, semi-synthetic, first-in-class pleuromutilin antibiotic for systemic use in humans. In December of 2018, Nabriva filed a New Drug Application (NDA) for use of lefamulin in the treatment of community-acquired bacterial pneumonia (CABP) in adults.This study involves giving a single IV dose of lefamulin to hospitalized pediatric subjects who are receiving standard of care systemic antibiotic therapy for the prevention or treatment of a confirmed or suspected bacterial infection. The results of this study will support dose selection for future pediatric studies of lefamulin.

Related Clinical Trials

Click on the category you are interested in.

Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.